Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Feasibility and safety of cangrelor in patients with suboptimal P2Y₁₂ inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Eur Heart J Open. 2021 Oct 18;1(3):oeab028. doi: 10.1093/ehjopen/oeab028. eCollection 2021 Nov.

Abi Selvarajah¹, Annerieke H Tavenier¹, Wilbert L Bor², Vital Houben³, Saman Rasoul^{3

4}, Eliza Kaplan⁵, Koen Teeuwen⁶, Sjoerd H Hofma⁷, Erik Lipsic⁸, Giovanni Amoroso⁹, Maarten A H van Leeuwen¹, Jur M Ten Berg^{2

10}, Arnoud W J van 't Hof^{1

3

4

10}, Renicus S Hermanides¹

¹ Department of Cardiology, Isala Hospital, Zwolle, The Netherlands.
² Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
³ Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands.
⁴ Department of Cardiology, MUMC+, Maastricht, the Netherlands.
⁵ Department of Cardiology, Venlo VieCuri Medical Center, Venlo, The Netherlands.
⁶ Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.
⁷ Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
⁸ Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
⁹ Department of Cardiology, OLVG Hospital, Amsterdam, The Netherlands.
¹⁰ Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

No abstract available

Keywords: Cangrelor; P2Y12 inhibitors; Percutaneous coronary intervention; Platelet inhibition.